Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial,…
Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (the “Company” or “Alps Group”), the…